<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974594</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-TAS-102-I-02</org_study_id>
    <nct_id>NCT03974594</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients</brief_title>
  <official_title>Single-Dose, Randomized, Open-Label, Two-Way Crossover Study to Evaluate the Bioequivalence of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients Under Fasting or Postprandial Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trifluridine and Tipiracil Tablets is a nucleoside anti-metabolic and anti-cancer compound&#xD;
      developed by Taiho (Dapeng) Co., Ltd., Japan, for the treatment of advanced colorectal cancer&#xD;
      that inoperable resection, and progressed or relapsed after standard treatment. This study&#xD;
      mainly evaluates bioequivalence, safety and tolerance of Trifluridine and Tipiracil Tablets&#xD;
      in colorectal cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-infinity)</measure>
    <time_frame>3 days</time_frame>
    <description>The AUC(0-infinity) is area under the serum concentration-time curve from time zero to infinite time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>3 days</time_frame>
    <description>The AUC(0-t) is area under the serum concentration-time curve from time zero to t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on Peak Plasma Concentration (Cmax)</measure>
    <time_frame>3 days</time_frame>
    <description>The Cmax is observed maximum serum concentration, taken directly from the serum concentration-time profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Security Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Trifluridine and Tipiracil Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS-102</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trifluridine and Tipiracil Tablets</intervention_name>
    <description>Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle</description>
    <arm_group_label>Trifluridine and Tipiracil Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-102</intervention_name>
    <description>TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle</description>
    <arm_group_label>TAS-102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-70 years old, life expectancy ≥ 3 months.&#xD;
&#xD;
          2. Histologically confirmed colon or rectal adenocarcinoma.&#xD;
&#xD;
          3. Has not received anti-tumor therapy before 4 weeks of first dose or Traditional&#xD;
             Chinese Medicine anti-tumor therapy before 2 weeks of first dose.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          5. Has ability to take oral medication.&#xD;
&#xD;
          6. The main organs function are normally, the following criteria are met:&#xD;
&#xD;
               1. Hemoglobin (HB) ≥ 100 g / L;&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥1.5×109/L;&#xD;
&#xD;
               3. Platelets (PLT) ≥ 80 × 109 / L;&#xD;
&#xD;
               4. Total serum bilirubin (TBIL) ≤ 1.5 × ULN;&#xD;
&#xD;
               5. Alanine transaminase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 × ULN (when&#xD;
                  the liver is invaded，AST ≤ 5×ULN);&#xD;
&#xD;
               6. Serum creatinine ≤ 132.6 μmol / L.&#xD;
&#xD;
          7. Male or female subjects should agree to use an adequate method of contraception&#xD;
             starting with the first dose of study therapy through 6 months after the last dose of&#xD;
             study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or&#xD;
             breastfeeding women, and a negative pregnancy test are received within 7 days before&#xD;
             the randomization.&#xD;
&#xD;
          8. Understood and signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has serious diseases , including but not limited to:&#xD;
&#xD;
               1. Has diagnosed and/or treated additional malignancy within 5 years prior to&#xD;
                  randomization. Exceptions include carcinoma in situ of cervix, non-melanoma skin&#xD;
                  cancer and superficial bladder tumor;&#xD;
&#xD;
               2. Has brain metastases;&#xD;
&#xD;
               3. Has active infection (such as infection caused body temperature ≥ 38 ° C);&#xD;
&#xD;
               4. Has pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
                  drainage before 4 weeks of first dose;&#xD;
&#xD;
               5. Has intestinal obstruction, pulmonary fibrosis, renal failure, liver failure or&#xD;
                  symptomatic cerebrovascular disease;&#xD;
&#xD;
               6. Has uncontrolled diabetes (fasting blood glucose (FBG) &gt; 10mmol/L);&#xD;
&#xD;
               7. Has myocardial infarction, severe/unstable angina pectoris, New York Heart&#xD;
                  Association (NYHA) grade III or IV symptomatic congestive heart failure within 12&#xD;
                  months prior to first dose;&#xD;
&#xD;
               8. Has gastrointestinal bleeding;&#xD;
&#xD;
               9. Has HIV infection, or active hepatitis B or C;&#xD;
&#xD;
              10. Has a history of organ transplants or autoimmune disease required&#xD;
                  immunosuppressive therapy;&#xD;
&#xD;
              11. Has increased risk associated with participating in the study or taking the study&#xD;
                  drug, or mental disorders may interfere with the results of the study.&#xD;
&#xD;
          2. Has received any of the following treatments before the first dose:&#xD;
&#xD;
               1. Has received partial or total gastrectomy;&#xD;
&#xD;
               2. Has surgery (such as laparotomy, thoracotomy, and laparoscopic resection of the&#xD;
                  viscera and/or unhealed wounds) within 4 weeks;&#xD;
&#xD;
               3. Has any study drug within 4 weeks.&#xD;
&#xD;
          3. Prior therapy with TAS-102.&#xD;
&#xD;
          4. Has adverse events caused by previous therapy except alopecia that did not recover to&#xD;
             ≤ grade 2.&#xD;
&#xD;
          5. Pregnant or lactating woman.&#xD;
&#xD;
          6. Subjects who, in the opinion of the investigators, should not participate in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Helong Zhang, Doctor</last_name>
    <phone>135 1912 8910</phone>
    <email>cntdccc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tangdu Hospital,Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helong Zhang, Doctor</last_name>
      <phone>135 1912 8910</phone>
      <email>cntdccc@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

